Alkermes
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
ALKS Key Statistics
ALKS News
Advertisement Most Popular Narrative: 35.1% Undervalued Alkermes (ALKS) just made a move that is getting investors’ attention. The company announced Joshua Re...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Analyst ratings
71%
of 17 ratingsMore ALKS News
Healthcare Alkermes appoints new CFO Sep. 12, 2025 9:08 AM ET Alkermes plc (ALKS) Stock By: Khushi Singh, SA News Editor 5 Share Save ( <1min ) Comments Josh...
Alkermes recently announced positive results from the Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1, demonstrating significant improvements in wa...
Needham lowered the firm’s price target on Alkermes (ALKS) to $43 from $45 and keeps a Buy rating on the shares following Phase 2 data from the Vibrance-1 study...
Analyst Jason Gerberry of Bank of America Securities maintained a Hold rating on Alkermes, retaining the price target of $33.00. Elevate Your Investing Strategy...
Jefferies notes that Centessa (CNTA) shares rose 18% in reaction to competitors Takeda (TAK) and Alkermes’ (ALKS) narcolepsy data reported at World Sleep as dat...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...